Inflammatory breast carcinoma

Summary

Inflammatory breast carcinoma (MONDO:0006804) is a cancer with 2 cohort genes (2 CIViC-evidence somatic drivers) and 46 clinical trials. Molecularly, MMP2 SERUM LEVELS confers sensitivity to Bevacizumab in Inflammatory Breast Carcinoma (CIViC Level B); 1 further subtype–drug associations are mapped below. Top therapeutic interventions include cyclophosphamide anhydrous, dexrazoxane, and epirubicin.

At a glance

• Classification: Cancer
• Cohort genes: 2
• Clinical trials: 46
• Precision-medicine evidence (CIViC): 2 subtype–drug associations

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	inflammatory breast carcinoma
Mondo ID	MONDO:0006804
EFO	EFO:1000984
MeSH	D058922
Orphanet	694963
DOID	DOID:6263
NCIT	C4001
SNOMED CT	254840009
UMLS	C0278601
MedGen	75841
GARD	0006784
MedDRA	10006205
Is cancer (heuristic)	yes

Also known as: breast cancer, inflammatory · IBC · inflammatory breast cancer · inflammatory breast carcinoma · inflammatory carcinoma of breast · inflammatory carcinoma of the breast · mastitis Carcinomatosa · mastitis carcinomatosa

Data availability: 13 cell lines.

Disease family

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › breast adenocarcinoma › inflammatory breast carcinoma

Related subtypes (12): breast lobular carcinoma, mammary Paget disease, signet ring cell breast carcinoma, breast mucinous cystadenocarcinoma, mucoepidermoid breast carcinoma, adenoid cystic breast carcinoma, sebaceous breast carcinoma, oncocytic breast carcinoma, breast malignant eccrine spiradenoma, breast ductal adenocarcinoma, lobular breast carcinoma in situ, mixed lobular and ductal breast carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
MMP2			CIViC #3549
MMP9			CIViC #3553

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
MMP2	Orphanet:371428	Multicentric osteolysis-nodulosis-arthropathy spectrum
MMP9	Orphanet:1040	Metaphyseal anadysplasia

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
MMP2	HGNC:7166	ENSG00000087245	P08253	72 kDa type IV collagenase	civic_evidence
MMP9	HGNC:7176	ENSG00000100985	P14780	Matrix metalloproteinase-9	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
MMP2	72 kDa type IV collagenase	Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture.
MMP9	Matrix metalloproteinase-9	Matrix metalloproteinase that plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration.

Protein-family classification

Druggable: 2 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Protease	2	36.6×	7e-04

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
MMP2	Protease	yes	3.4.24.24	FN_type2_dom, Hemopexin-like_dom, Pept_M10_metallopeptidase
MMP9	Protease	yes	3.4.24.35	FN_type2_dom, Hemopexin-like_dom, Pept_M10_metallopeptidase

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
gall bladder	1
mucosa of stomach	1
stromal cell of endometrium	1
periodontal ligament	1
tibia	1
trabecular bone tissue	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
MMP2	262	ubiquitous	marker	stromal cell of endometrium, gall bladder, mucosa of stomach
MMP9	204	broad	marker	periodontal ligament, trabecular bone tissue, tibia

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
MMP9	6,708
MMP2	4,603

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
MMP9	P14780	29
MMP2	P08253	14

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 27. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Activation of Matrix Metalloproteinases	2	308.6×	2e-04	MMP2, MMP9
EPH-ephrin mediated repulsion of cells	2	219.6×	2e-04	MMP2, MMP9
Collagen degradation	2	175.7×	2e-04	MMP2, MMP9
Extra-nuclear estrogen signaling	2	170.4×	2e-04	MMP2, MMP9
EPH-Ephrin signaling	2	165.5×	2e-04	MMP2, MMP9
ESR-mediated signaling	2	128.3×	3e-04	MMP2, MMP9
Degradation of the extracellular matrix	2	117.7×	3e-04	MMP2, MMP9
Interleukin-4 and Interleukin-13 signaling	2	102.9×	3e-04	MMP2, MMP9
Signaling by Nuclear Receptors	2	102.0×	3e-04	MMP2, MMP9
Signaling by Interleukins	2	64.2×	6e-04	MMP2, MMP9
Extracellular matrix organization	2	63.1×	6e-04	MMP2, MMP9
Axon guidance	2	45.1×	0.001	MMP2, MMP9
Nervous system development	2	42.9×	0.001	MMP2, MMP9
Cytokine Signaling in Immune system	2	40.8×	0.001	MMP2, MMP9
Collagen formation	1	228.4×	0.008	MMP9
Developmental Biology	2	14.5×	0.008	MMP2, MMP9
Immune System	2	13.0×	0.009	MMP2, MMP9
Signaling by SCF-KIT	1	124.1×	0.012	MMP9
Assembly of collagen fibrils and other multimeric structures	1	100.2×	0.013	MMP9
Signal Transduction	2	10.2×	0.013	MMP2, MMP9
MAPK6/MAPK4 signaling	1	68.0×	0.019	MMP2
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	1	43.3×	0.028	MMP2
Signaling by Receptor Tyrosine Kinases	1	25.8×	0.045	MMP9
Dengue Virus-Host Interactions	1	22.8×	0.049	MMP9
Innate Immune System	1	12.8×	0.083	MMP9
Neutrophil degranulation	1	11.5×	0.088	MMP9
Metabolism of proteins	1	6.2×	0.155	MMP2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
cellular response to UV-A	2	1404.3×	3e-05	MMP2, MMP9
response to amyloid-beta	2	991.3×	3e-05	MMP2, MMP9
endodermal cell differentiation	2	495.6×	7e-05	MMP2, MMP9
positive regulation of vascular associated smooth muscle cell proliferation	2	432.1×	7e-05	MMP2, MMP9
collagen catabolic process	2	391.9×	7e-05	MMP2, MMP9
extracellular matrix disassembly	2	366.4×	7e-05	MMP2, MMP9
ephrin receptor signaling pathway	2	343.9×	7e-05	MMP2, MMP9
extracellular matrix organization	2	122.1×	5e-04	MMP2, MMP9
negative regulation of cation transmembrane transport	1	8426.0×	7e-04	MMP9
negative regulation of epithelial cell differentiation involved in kidney development	1	8426.0×	7e-04	MMP9
cell migration	2	61.5×	0.001	MMP2, MMP9
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway	1	2106.5×	0.002	MMP2
intramembranous ossification	1	1404.3×	0.003	MMP2
blood vessel maturation	1	1203.7×	0.003	MMP2
trophoblast cell migration	1	1203.7×	0.003	MMP2
peripheral nervous system axon regeneration	1	1053.2×	0.003	MMP2
bone trabecula formation	1	1053.2×	0.003	MMP2
ovulation from ovarian follicle	1	936.2×	0.003	MMP2
luteinization	1	936.2×	0.003	MMP2
parturition	1	936.2×	0.003	MMP2
prostate gland epithelium morphogenesis	1	936.2×	0.003	MMP2
proteolysis	2	34.2×	0.003	MMP2, MMP9
negative regulation of vasoconstriction	1	842.6×	0.003	MMP2
regulation of neuroinflammatory response	1	702.2×	0.003	MMP9
tissue remodeling	1	648.1×	0.003	MMP2
positive regulation of keratinocyte migration	1	648.1×	0.003	MMP9
cellular response to fluid shear stress	1	648.1×	0.003	MMP2
positive regulation of DNA binding	1	601.9×	0.004	MMP9
response to hyperoxia	1	561.7×	0.004	MMP2
macrophage chemotaxis	1	468.1×	0.004	MMP2

Therapeutics

Drugs indicated for this disease

0 approved, 10 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Carboplatin	Phase 3 (in late-stage trials)
Cisplatin	Phase 3 (in late-stage trials)
Doxorubicin	Phase 3 (in late-stage trials)
Epirubicin	Phase 3 (in late-stage trials)
Ferric Carboxymaltose	Phase 3 (in late-stage trials)
Fluorouracil	Phase 3 (in late-stage trials)
Paclitaxel	Phase 3 (in late-stage trials)
Pertuzumab	Phase 3 (in late-stage trials)
Trastuzumab	Phase 3 (in late-stage trials)
Trastuzumab Emtansine	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Aldesleukin, Atorvastatin, Busulfan, Capecitabine, Denosumab, Durvalumab, Eribulin, Filgrastim, Ipilimumab, Letrozole, Melphalan, Nivolumab, Pembrolizumab, Ruxolitinib, Sargramostim, Thiotepa, Tipifarnib, Trastuzumab Deruxtecan.

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 0

Druggability breadth: 2 of 2 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
MMP2	DOXYCYCLINE
MMP9	CHLOROXINE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
MMP2	26	4
MMP9	26	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
DOXYCYCLINE	4	MMP2
TILUDRONIC ACID	4	MMP2
DAUNORUBICIN	4	MMP2
ZOLEDRONIC ACID	4	MMP2, MMP9
DOXORUBICIN	4	MMP2
CHLORHEXIDINE	4	MMP2, MMP9
CHLOROXINE	4	MMP9
BUDESONIDE	4	MMP9
PRAZOSIN	4	MMP9
SECOBARBITAL	4	MMP9
DACARBAZINE	4	MMP9
ECONAZOLE	4	MMP9
BUSULFAN	4	MMP9
CAFFEIC ACID	3	MMP2, MMP9
MEDRONIC ACID	3	MMP2
MARIMASTAT	3	MMP2, MMP9
EPIGALOCATECHIN GALLATE	3	MMP2
QUERCETIN	3	MMP2, MMP9
ACLARUBICIN	3	MMP2
PRINOMASTAT	3	MMP2, MMP9
CURCUMIN	3	MMP9
CIPEMASTAT	2	MMP2, MMP9
LUTEOLIN	2	MMP2, MMP9
ILOMASTAT	2	MMP2, MMP9
TOSEDOSTAT	2	MMP2, MMP9
SOLIMASTAT	2	MMP2, MMP9
TANOMASTAT	2	MMP2, MMP9
BATIMASTAT	2	MMP2, MMP9
UBENIMEX	2	MMP2
CTS-1027	2	MMP2, MMP9

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
MMP2	771	Binding:735, ADMET:28, Functional:7, Unclassified:1
MMP9	713	Binding:685, ADMET:20, Functional:8

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
MMP2	3.4.24.24	gelatinase A
MMP9	3.4.24.35	gelatinase B

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
MMP2	771
MMP9	713

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

29 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
DOXYCYCLINE	4	MMP2
TILUDRONIC ACID	4	MMP2
DAUNORUBICIN	4	MMP2
ZOLEDRONIC ACID	4	MMP2, MMP9
DOXORUBICIN	4	MMP2
CHLORHEXIDINE	4	MMP2, MMP9
CHLOROXINE	4	MMP9
BUDESONIDE	4	MMP9
PRAZOSIN	4	MMP9
SECOBARBITAL	4	MMP9
DACARBAZINE	4	MMP9
ECONAZOLE	4	MMP9
CAFFEIC ACID	3	MMP2, MMP9
MEDRONIC ACID	3	MMP2
MARIMASTAT	3	MMP2, MMP9
EPIGALOCATECHIN GALLATE	3	MMP2
QUERCETIN	3	MMP2, MMP9
ACLARUBICIN	3	MMP2
PRINOMASTAT	3	MMP2, MMP9
CURCUMIN	3	MMP9
CIPEMASTAT	2	MMP2, MMP9
LUTEOLIN	2	MMP2, MMP9
ILOMASTAT	2	MMP2, MMP9
TOSEDOSTAT	2	MMP2, MMP9
SOLIMASTAT	2	MMP2, MMP9
TANOMASTAT	2	MMP2, MMP9
BATIMASTAT	2	MMP2, MMP9
UBENIMEX	2	MMP2
CTS-1027	2	MMP2, MMP9

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	MMP2, MMP9
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 46.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	19
Not specified	9
PHASE3	6
PHASE1	5
PHASE1/PHASE2	3
PHASE2/PHASE3	2
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02221999	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients
NCT00016276	PHASE3	TERMINATED	Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
NCT01426880	PHASE2/PHASE3	COMPLETED	Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
NCT01583426	PHASE3	COMPLETED	Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)
NCT02125344	PHASE3	COMPLETED	A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
NCT02324088	PHASE3	COMPLETED	Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer
NCT02879513	PHASE3	UNKNOWN	Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy
NCT05415215	PHASE3	COMPLETED	A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
NCT01525966	PHASE2	ACTIVE_NOT_RECRUITING	Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
NCT01730833	PHASE2	ACTIVE_NOT_RECRUITING	Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
NCT02411656	PHASE2	ACTIVE_NOT_RECRUITING	Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
NCT02623972	PHASE2	ACTIVE_NOT_RECRUITING	A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
NCT02876107	PHASE2	ACTIVE_NOT_RECRUITING	Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
NCT02876302	PHASE2	ACTIVE_NOT_RECRUITING	Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
NCT03515798	PHASE2	ACTIVE_NOT_RECRUITING	Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer
NCT05383196	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Onvansertib + Paclitaxel In TNBC
NCT05795101	PHASE2	RECRUITING	TRUDI: TDXD+Durva in HER2+/Low IBC
NCT00003199	PHASE2	COMPLETED	Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
NCT00049114	PHASE2	COMPLETED	Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
NCT00070252	PHASE1/PHASE2	COMPLETED	Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
NCT00513695	PHASE2	COMPLETED	Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
NCT01417286	PHASE2	COMPLETED	Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer
NCT01641406	PHASE2	UNKNOWN	Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer
NCT01938833	PHASE1/PHASE2	TERMINATED	Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
NCT02199418	PHASE2	COMPLETED	Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer
NCT02658812	PHASE2	TERMINATED	Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery
NCT02682693	PHASE2	COMPLETED	Denosumab as an add-on Neoadjuvant Treatment (GeparX)
NCT02892734	PHASE2	TERMINATED	Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
NCT03184558	PHASE2	TERMINATED	Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
NCT03872388	PHASE2	TERMINATED	Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
NCT00004074	PHASE1	COMPLETED	Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
NCT00891280	PHASE1	UNKNOWN	Dose-escalation Study of Oral CX-4945
NCT01880385	PHASE1	UNKNOWN	Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer
NCT02227082	PHASE1	COMPLETED	Olaparib and Radiotherapy in Inoperable Breast Cancer
NCT04660929	PHASE1	UNKNOWN	CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
NCT00986609	EARLY_PHASE1	COMPLETED	MUC1 Vaccine for Triple-negative Breast Cancer
NCT01894451	EARLY_PHASE1	COMPLETED	Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
NCT00477100	Not specified	RECRUITING	Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
NCT04030507	Not specified	RECRUITING	Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
NCT04636710	Not specified	RECRUITING	Refining Local-Regional Therapy for IBC

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CYCLOPHOSPHAMIDE ANHYDROUS	4	10
DEXRAZOXANE	4	3
EPIRUBICIN	4	3
PERTUZUMAB	4	2
TRASTUZUMAB	4	2
ALDESLEUKIN	4	1
BUSULFAN	4	1
ERIBULIN	4	1
FERRIC CARBOXYMALTOSE	4	1
LETROZOLE	4	1
PACLITAXEL	4	1
ROMIDEPSIN	4	1
SARGRAMOSTIM	4	1
SUNITINIB MALATE	4	1
TALIMOGENE LAHERPAREPVEC	4	1
TAMOXIFEN CITRATE	4	1
THIOTEPA	4	1
TRASTUZUMAB DERUXTECAN	4	1
TRASTUZUMAB EMTANSINE	4	1
TIPIFARNIB	3	2
ZENIDOLOL	2	2
EDODEKIN ALFA	2	1
ONVANSERTIB	2	1
CHEMBL48	0	1
CHEMBL3109278	0	1
CHEMBL4066465	0	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 2 predictive associations from 2 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
MMP2 SERUM LEVELS	Bevacizumab	Sensitivity/Response	CIViC B	EID1156
MMP9 SERUM LEVELS	Bevacizumab	Resistance	CIViC B	EID1157